<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "ich-icsr-v2.1.dtd">
<ichicsr>
  <ichicsrmessageheader>
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>1.0</messageformatrelease>
    <messagenumb>2025-07</messagenumb>
    <messagesenderidentifier>FDA CDER</messagesenderidentifier>
    <messagereceiveridentifier>Public Use</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20250717084352</messagedate>
  </ichicsrmessageheader>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>25135630</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20250716</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20250328</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20250328</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>746694</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>6</sendertype>
      <senderorganization>FDA-CTU</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>61.65</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Influenza</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Loss of consciousness</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Head injury</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebral haemorrhage</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TADALAFIL</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>40 MG DAILY ORAL ?</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Pulmonary arterial hypertension</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220610</drugstartdate>
        <activesubstance>
          <activesubstancename>TADALAFIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REMODULIN</medicinalproduct>
        <activesubstance>
          <activesubstancename>TREPROSTINIL</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>25135656</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20250717</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20250328</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20250328</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>746722</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>6</sendertype>
      <senderorganization>FDA-CTU</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>83</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Death</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ONDANSETRON</medicinalproduct>
        <drugstructuredosagenumb>8</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : 3 TIMES A DAY;?</drugdosagetext>
        <drugadministrationroute>060</drugadministrationroute>
        <drugindication>Hepatocellular carcinoma</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20250121</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20250320</drugenddate>
        <activesubstance>
          <activesubstancename>ONDANSETRON</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20250321</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>25135657</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20250717</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20250328</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20250328</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>746705</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>6</sendertype>
      <senderorganization>FDA-CTU</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>28.0</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic product effect decreased</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SKYRIZI</medicinalproduct>
        <drugstructuredosagenumb>360</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Crohn^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
